Antibe Therapeutics Inc. Banner Image

Antibe Therapeutics Inc.

  • Ticker ATE
    Exchange TSX-V More
  • Industry Biotechnology More
  • Sector Healthcare More
Antibe Therapeutics Inc. Logo Image
  • 11-50 Employees
  • Based in Toronto, Ontario
Antibe Therapeutics is a publicly traded biotechnology company pursuing a breakthrough advance in the treatment of inflammation. Their drug pipeline addresses major markets in non-addictive management of chronic and post-surgical pain. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety in the treatment of chronic pain, a condition that affects more thanMore 50 million Americans alone. Their second pipeline drug is intended to replace a range of opioids, addressing a vast and pressing public health concern. Their third drug is a safer daily aspirin -- delivering anti-stroke and anti-cancer benefits without damage to the digestive tract.
4.7 / 5.0 (65)

Antibe Therapeutics Inc. reports have an aggregate usefulness score of 4.7 based on 65 reviews.

Antibe Therapeutics Inc.

Most Recent Annual Report

Antibe Therapeutics Inc.
MOST RECENT 2023 Annual Report

Older/Archived Annual Reports

Antibe Therapeutics Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!